...
首页> 外文期刊>Journal of Pharmacy and Pharmacology >In-vitro in-vivo correlation models for glibenclamide after administration of metformin/glibenclamide tablets to healthy human volunteers.
【24h】

In-vitro in-vivo correlation models for glibenclamide after administration of metformin/glibenclamide tablets to healthy human volunteers.

机译:向健康人类志愿者服用二甲双胍/格列本脲片剂后,格列本脲的体外体内相关模型。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In this study, level C and A in-vitro in-vivo correlation (IVIVC) models were developed for glibenclamide. In-vitro dissolution data were collected for the glibenclamide component of three metformin/glibenclamide tablets using a USP Type II apparatus. In-vivo plasma concentration data were obtained after administration of the prototype formulations to 24 healthy volunteers and subject to deconvolution analysis to obtain percentage in-vivo absorbed profiles. Multiple linear level C models were developed for CMAX and AUC(0-48) using percentage in-vitro dissolved data at 10, 45 and 120 min. Initially, the level A model was constructed for the first 2 h only, based on availability of in-vitro data. Another level A model was attempted using a time-scaled approach, with percentage in-vivo absorbed at time t and percentage in-vitro dissolved at time t/I as the correlating data. Internal predictability was evaluated for the level C and time-scaled level A models. For all level C approaches, linear regression models with r2 > 0.99 were determined. The prediction errors (% PE) for Cmax and AUC(0-48) were less than 1% for all formulations at all three chosen time points. The deconvolution analysis indicated biphasic absorption for glibenclamide, with one phase occurring at 2-3h and another at 6-12h after dose administration. The level A model using 2-h data was not unique for all formulations and was therefore not developed. The time-scaling factor I correlated highly (r2 = 0.99) with in vitro mean dissolution time (MDT). A linear regression time scaled model (r2 = 0.97) was successfully developed using in-vitro and in-vivo data from all 3 formulations. However, the internal predictability of the time-scaled model was poor, with % PE values for Cmax and AUC(0-48) being as much as 30.5% and 18.7%, respectively. The results indicate that level C models have good internal predictability. Though a time-scaled level A IVIVC model was successfully developed, the model was found to have poor internal predictability.
机译:在这项研究中,为格列本脲开发了C级和A级体外相关(IVIVC)模型。使用USP II型仪器收集三枚二甲双胍/格列本脲片剂的格列本脲成分的体外溶出数据。在向24位健康志愿者服用原型制剂后获得体内血浆浓度数据,并进行去卷积分析,以获得体内吸收百分比数据。使用10、45和120分钟时的体外溶出数据百分比,针对CMAX和AUC(0-48)开发了多个线性C级模型。最初,根据体外数据的可用性,仅在最初的2小时内构建了A级模型。尝试使用时间标度的方法建立另一个A级模型,其中在时间t吸收的体内百分比和在时间t / I溶解的体外百分比作为相关数据。内部可预测性在C级和时标A级模型中进行了评估。对于所有C级方法,确定了r2> 0.99的线性回归模型。在所有三个选定的时间点,所有配方的Cmax和AUC(0-48)的预测误差(%PE)均小于1%。解卷积分析表明格列苯脲为双相吸收,给药后一相出现在2-3h,另一相出现在6-12h。使用2小时数据的A级模型并非在所有配方中都是唯一的,因此尚未开发。时间比例因子I与体外平均溶出时间(MDT)高度相关(r2 = 0.99)。使用所有3种配方的体外和体内数据成功开发了线性回归时间标度模型(r2 = 0.97)。但是,时间尺度模型的内部可预测性较差,Cmax和AUC(0-48)的%PE值分别高达30.5%和18.7%。结果表明,C级模型具有良好的内部可预测性。尽管成功开发了时标A级IVIVC模型,但发现该模型的内部可预测性较差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号